MedTrace Logo

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy

NCT01539447 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2022-07-14

No results posted yet for this study

Summary

In a brief summary the study would like to evaluate the effectiveness of Naproxen in preventing radiographically detected heterotopic ossification following hip arthroscopy for the treatment of femoroacetabular impingement.

Conditions

Interventions

DRUG

Naproxen

• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1

DRUG

placebo

• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1

Sponsors & Collaborators

Principal Investigators

  • Stephen Aoki, M.D. · University of Utah Orthopedics Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2022-03-16
Completion
2022-03-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539447 on ClinicalTrials.gov